29 / 48
29
Symposia
/ Preliminary Scientific Programme
WFSBP 2017
T50: VIOLENCE: BASIC/CLINICAL
S-46
08:30–10:00
Neurobiology and psychopharmacology of aggressive
behaviour: Where are we?
Chair:
Stefano Comai, Italy
Co-Chair: Gabriella Gobbi, Canada
S-46-001
Neurobiology and biomarkers of aggression
Stefano Comai, Italy
S-46-002
Clinical management of aggression in childhood and
adolescence
Florian D. Zepf, Australia
S-46-003
Drug abuse/dependence and aggressive behaviour
Gabriella Gobbi, Canada
S-46-004
Epilepsy, antiepileptic drugs and aggression
Martin J. Brodie, United Kingdom
T11: DEPRESSION: BASIC/CLINICAL
S-47
08:30–10:00
Catecolamines, anhedonia and depression
Chair:
Jose Luis Ayuso, Spain
Co-Chair: Victoria Valdez, Ecuador
S-47-001
Catecholamines, reward circuits and depression
Gregor Hasler, Switzerland
S-47-002
Positive affects and depression
Jorge Tellez-Vargas, Colombia
S-47-003
Anhedonia and suicide behavior
Maurizio Pompili, Italy
S-47-004
Exploring the role of proinflammatory cytokines in
anhedonia
Ruby Castilla-Puentes, USA
T32: PHARMACOGENETICS
S-48
11:15–12:45
Pharmacogenetics of drug defense and
neuroprotection: From the Neandertal to the modern
humans
Chair:
Julia Stingl, Germany
Co-Chair: Magnus Ingelman-Sundberg, Sweden
S-48-001
The evolutionary aspect of trait biomarkers in drug
metabolism and neuroprotection
Magnus Ingelman-Sundberg, Sweden
S-48-002
Pharmacogenetic polymorphisms on behavioral and
structural brain phenotypes uncovered by neuroimaging
data
Roberto Viviani, Austria
S-48-003
Prevention of drug toxicity to the brain: The vulnerable
brain and ADRs of nervous system disorders
Julia Stingl, Germany
S-48-004
Pharmacogenetic factors in neuroprotection during
neurodevelopment
Karim Barakat, Germany
T11: DEPRESSION: BASIC/CLINICAL
S-49
11:15–12:46
Evidence-based guidelines for treatment of major
depressive disorder: Contrasting views across the
world
Chair:
Roumen Milev, Canada
Co-Chair: Allan Young, United Kingdom
S-49-001
A subequatorial view: The new RANZCP guidelines
Gin Malhi, Australia
S-49-002
The evolution of the CANMAT guidelines
Raymond Lam, Canada
S-49-003
The view from the UK: BAP guidelines for Mood Disor-
ders (MD)
Allan Young, United Kingdom
S-49-004
Even the best guidelines don't work unless they are
implemented
Sagar Parikh, USA
WED